ASCO Meeting 2022 Participation

Awards and Honors

2022 Conquer Cancer Young Investigator Awards
Julia Foldi
James Laird

Fellow of the American Society of Clinical Oncology (FASCO)
Patricia LoRusso

Member, Annual Meeting Scientific Program Committee: Breast Cancer – Metastatic
Maryam B. Lustberg

Giant of Cancer--Lung Cancer
Roy S. Herbst, MD, PhD

Thursday, June 2

Presentation
Addressing Gender Harassment in Oncology
Presenter: Maryam Lustberg

Friday, June 3

Oral Abstract Session
Lung Cancer—Non-Small Cell Metastatic
Overall Survival From A Phase II Randomized Study Of Ramucirumab Plus Pembrolizumab Versus Standard Of Care For Advanced Non–Small Cell Lung Cancer Previously Treated With Immunotherapy: Lung-MAP Nonmatched Substudy S1800A
Senior Author: Roy S. Herbst
Session: June 3; 2:00 – 5:00PM ET
Location: Hall D1 and live stream

Case Based Panel
Ethical Dilemmas among Genetic Testing
Policy Implications for On-the-Ground Genetic Counseling
Speaker: Amanda C. Ganzak
Session: June 3; 5:30 – 6:30PM ET
Location: S504 and on demand

Oral Abstract Session
Genitourinary Cancer—Kidney and Bladder
Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314
Author: Daniel P. Petrylak
Session: June 3; 3:45 – 6:45 PM ET
Location: Arie Crown Theater and live stream
Saturday, June 4

Clinical Science Symposium
ctDNA: Dawn of a New Era
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP)
Authors: Eric P. Winer, Ian E. Krop
Session: June 4; 9:00 – 10:30AM ET
Location: Hall D1 and live stream

Oral Abstract Session
Breast Cancer—Metastatic
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
Panelist and Presenter: Ian E. Krop
Session: June 4; 2:15 – 5:15PM ET
Location: Hall D1 and live stream

Oral Abstract Sessions
Developmental Therapeutics—Immunotherapy
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor γ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
Author: Patricia LoRusso
Dose escalation of a phase 1b/2 study of modakafusp αlfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors
Author: Navid Hafez
Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)
Senior Author: Patricia LoRusso
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors
Author: Patricia LoRusso
Session: June 4; 2:15 – 5:15PM ET
Location: Hall B1 and live stream

Poster Session
Gastrointestinal Cancer – Colorectal and Anal
329 - Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Presenter: Michael Cecchini
Session: June 4; 9:00AM – 12:00PM ET
Location: Hall A and on demand

Poster Session
Genitourinary Cancer—Kidney and Bladder
73 - Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible
Presenter: Daniel P. Petrylak
Session: June 4; 2:15 – 5:15PM ET
Location: Hall A and on demand
**Poster Session**
Gynecologic Cancer

**472 - Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study**
Presenter: Alessandro Santin
Session: June 4; 2:15 – 5:15PM ET
Location: Hall A and on demand

**Poster Session**
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**207 – Treatment Patterns and Real-world Effectiveness of Rituximab Maintenance in Older Patients with Mantle cell Lymphoma: A Population-based analyses**
Presenter: Mengyang Di
Session: June 4; 9:00AM – 12:00PM ET
Location: Hall A and on demand

**Poster Session**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

**7032 – Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)**
**7056 - Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial**
Author: Amer M. Zeidan
Session: June 4; 9:00AM – 12:00PM ET
Location: Hall A and on demand

**Poster Session**
Hematologic Malignancies—Plasma Cell Dyscrasia

**8057 - Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis**
Author: Lohith Gowda
Session: June 4; 9:00AM – 12:00PM ET
Location: Hall A and on demand

**Poster Session**
Care Delivery and Regulatory Policy

**1533 - Ancillary treatment referrals and visits after breast cancer surgery in a sociodemographically diverse population**
Authors: Danielle R. Heller, Elizabeth Rapp Berger, Scott Capozza, Rachel Adams Greenup, Tara B. Sanft (Senior)
Session: June 4; 2:15 – 5:15PM ET
Location: Hall A and on demand

**Poster Session**
Professional Development and Education Advances

**222 - Transdisciplinary research in energetics and cancer (TREC) training program for early career investigators**
Presenter: Melinda L. Irwin
Session: June 4; 2:15 – 5:15PM ET
Location: Hall A and on demand
**Poster Session**  
Symptoms and Survivorship  
**307 - Evaluation of social connectedness, loneliness, and anxiety among cancer survivors during the 2020-2021 winter surge of COVID-19 pandemic**  
Presenter: Hermine Poghosyan  
Session: June 4; 2:15 – 5:15PM ET  
Location: Hall A and on demand

**Poster Discussion Session**  
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia  
**Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)**  
Author: Iris Isufi  
Session: June 4; 4:00 – 5:30PM ET  
Location: E450 and on demand

**Poster Discussion Session**  
Genitourinary Cancer—Kidney and Bladder  
**Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma**  
Senior Author: Daniel P. Petrylak  
Session: June 4; 5:30PM – 7:00PM ET  
Location: Arie Crown Theater and live stream

**Poster Discussion Session**  
Symptoms and Survivorship  
**Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221**  
Author: Lajos Pusztai  
Session: June 4; 5:30 – 7:00PM ET  
Location: S404 and on demand

**Sunday, June 5**

**Oral Abstract Session**  
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary  
**4004 - A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors: Final Analysis of Efficacy and Association with MGMT (ECOG-ACRIN E2211)**  
Presenter: Pamela L. Kunz  
Session: June 5; 9:00AM – 12:00PM ET  
Location: Hall B1 and live stream

**Oral Abstract Session**  
**Melanoma/Skin Cancers**  
Chair & Panel Moderator: Harriet Kluger  
Session: June 5; 10:45AM – 1:45PM ET  
Location: S100a and live stream
**Education Session**  
Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges  
*The Role of Chemotherapy and Immunotherapy in Metastatic Head and Neck Cancer*  
Chair: Barbara Burtness  
Session: June 5; 9:00 – 10:15AM ET  
Location: E451 and on demand

**Education Session**  
High-Quality Survivorship Care: Best Practices and How to Make It Happen  
*Strategies for Effective Implementation of Survivorship Planning in Oncology Care*  
Speaker & Panelist: Tara B. Sanft  
Session: June 5; 9:00AM – 10:15AM ET  
Location: E350 and on demand

**Education Session**  
Tailor-Ax: Personalizing the Treatment of Axilla in Patients With Early-Stage Breast Cancer  
*What Is the Optimal Axillary Management for Early-Stage, Clinical Node–Negative Disease?*  
Chair: Rachel A. Greenup  
Session: June 5; 5:30 – 6:45PM ET  
Location: S100a and live stream

**Case-Based Panel**  
Less Is More: Practical De-Implementation Science Strategies to Improve Quality  
*A Medical Oncology/Community Oncology Perspective*  
Speaker & Panelist: Kerin B. Adelson  
Session: June 5; 5:30 – 6:30PM ET  
Location: E350 and on demand

**Plenary Session**  
*Discussion of LBA3*  
Discussant: Patricia LoRusso  
Session: June 5; 2:00 – 4:40PM ET  
Location: Hall B1 and on demand

**Poster Session**  
Central Nervous System Tumors  
373 - Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma  
Presenter: Kristina Fanucci  
Session: June 5; 9:00AM – 12:00PM ET  
Location: Hall A and on demand

**Poster Discussion Session**  
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology  
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors  
Author: Patricia LoRusso  
Session: June 5; 5:30PM – 7:00PM ET  
Location: Hall D2 and live stream
Monday, June 6

**Oral Abstract Session**

**Gastrointestinal Cancer—Colorectal and Anal**
Chair & Panel Moderator: Michael Cecchini
Session: June 6; 10:45AM – 1:45PM ET
Location: Arie Crown Theater and live stream

**Oral Abstract Session**

Symptoms and Survivorship
*Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study*
Presenter: Tara B. Sanft
Session: June 6; 12:30 – 3:00PM ET
Location: E450 and live stream

**Clinical Science Symposium**

Looking Everywhere for Determinants of Benefit From Immunotherapy
*Maximizing What We Learn from Slides*
Discussant: Kurt A. Schalper
Session: June 6; 2:15 – 3:45PM ET
Location: Arie Crown Theater and live stream

**Clinical Science Symposium**

Including the Excluded: Advancing Care for All Patients With Lung Cancer
Panelist: Sarah Goldberg
Session: June 6; 5:30 – 7:00PM ET
Location: Hall A and on demand

**Poster Session**

Breast Cancer—Local/Regional/Adjuvant
*365 - Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements*
Presenter: Kim RM Blenman
*371 - Deep learning algorithm to predict pathologic complete response to neoadjuvant chemotherapy for breast cancer prior to treatment*
Presenter: Rachel Choi
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

**Poster Session**

Breast Cancer – Metastatic
*403 - The mutational profile of ER-, PR+, HER2- metastatic breast cancer*
Presenter: Neal A. Fischbach
*405 - Targetable genomic mutations in young women with advanced breast cancer*
Presenter: Norin Ansari
Senior Authors: Mariya Rozenblit, Maryam B. Lustberg
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand
Poster Sessions
Lung Cancer—Non-Small Cell Metastatic

72 - A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
Presenter: Patricia LoRusso

9037 – First Report of Safety/Tolerability and Preliminary Antitumor Activity of CAN-2049 in Inadequate Responders to Immune Checkpoint Inhibitors for Stage III/IV NSCLC
Author: Roy S. Herbst

9044 – Dynamic Changes in Serum Analyte Levels Associated with Clinical Outcome in Squamous Cell Lung Cancer Trial SWOG Lung-MAP S1400I of Nivolumab +/- Ipilimumab
Authors: Roy S. Herbst, Scott N. Gettinger

9046 – Multiomics Profiling and Association with Molecular and Immune Features in Association with Benefits from Immunotherapy for Patients with Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer from the Phase III SWOG LungMAP S1400I Trial
Authors: Roy S. Herbst, Scott N. Gettinger

9060 – A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Nonsquamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (SWOG S1900C, Lung-MAP Sub-study NCT04173507)
Authors: Roy S. Herbst, Sarah B. Goldberg
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

Poster Session
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

64 – A Pilot Study of Ipilimumab and Nivolumab in Recurrent Extensive-stage Small Cell Lung Cancer after Platinum-based Chemotherapy
Presenter: Anne C. Chiang
Authors: Scott N. Gettinger, Sarah B. Goldberg, Fredrick H. Wilson, Benjamin R. Newton, Michael K. Cohenuram, Kert D. Sabbath, Ashita D. Talsania, Armand V. Russo, Roy S. Herbst, Kurt A. Schalper
Session: June 6; 9:00AM – 12:00PM ET
Location: Hall A and on demand

Poster Sessions
Melanoma/Skin Cancers

117 - Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy
Presenter: Harriet M. Kluger

148 - Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting
Presenter: Adriana Matutino Kahn
Session: June 6; 2:15 – 5:15PM ET
Location: Hall A and on demand
**Poster Sessions**

**Head and Neck Cancer**

*42 – Digital Spatial Profiling to Uncover Biomarkers of Immunotherapy Outcomes in Head and Neck Squamous Cell Carcinoma*

Presenter: Niki Gavrielatou

*89a – A Phase II/III Trial of Chemotherapy plus Chemotherapy plus Bevacizumab versus Atezolizumab plus Bevacizumab following Progression on Immune Checkpoint inhibition in Recurrent/Metastatic Head and Neck Cancers: ECOG-ACRIN EA3202*

Presenter: Aarti K. Bhatia

Session: June 6; 2:15 – 5:15PM ET

Location: Hall A and on demand

---

**Poster Session**

**Health Services Research and Quality Improvement**

*6543 – Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)*

Author: Roy S. Herbst

Session: June 6; 2:15 – 5:15PM ET

Location: Hall A and on demand

---

**Poster Discussion Session**

**Breast Cancer—Local/Regional/Adjuvant**

*Tailoring Therapy for HER2-Positive Breast Cancer*

Discussant/Panelist: Ian E. Krop

*Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC*

Presenter: Julia Foldi

Session: June 6; 2:15 – 3:45PM ET

Location: Hall B1 and live stream

---

**Poster Discussion Session**

**Melanoma/Skin Cancers**

*What’s Next? Treatment Choices After Anti-PD-1 Antibody*

Discussant: Kelly Olino

Session: June 6; 5:30 – 7:00PM ET

Location: S100a and live stream

---

**Tuesday, June 7**

**Oral Abstract Session**

**Breast Cancer—Local/Regional/Adjuvant**

*Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522*

Presenter/Panelist: Lajos Pusztai

Session: June 7; 10:45AM – 1:45PM ET

Location: Hall D1 and live stream

---

**Oral Abstract Session**

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

*A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)*

Author: Patricia LoRusso

Session: June 7; 10:45AM – 1:45PM ET

Location: S406 and live stream